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Extracellular vesicles (EVs) are released from all cell types, and carry a wide setup 
of proteins, nucleic acids, lipids and other cargo. The overall aim of this thesis is to 
explore EV-based immune therapy, but also to find clues on mechanisms of the 
inflammatory disease sarcoidosis, and of lung cancer. Exosomes from dendritic 
cells (DCs) pulsed with antigen can induce antigen-specific responses in vitro and 
in vivo. Study I is an investigation comparing exosomes and microvesicles (MVs), 
which may complement exosomes therapeutically. We found surprisingly similar 
phenotypes of the two EV subtypes, including size distribution and immune-
stimulatory molecule expression. However, when tested in vivo, only exosomes 
induced a significant antigen-specific CD8+ T cell response. Antigenic re-
stimulations ex vivo did, however, suggested that also MVs had such capacity, and 
both vesicle types induced antigen-specific IgG production. We further targeted the 
inflammatory disease pulmonary sarcoidosis in study II and study III with the aim 
to increase understanding of disease mechanisms, but also to search for disease 
biomarker candidates, and possible new treatment regimens. Broad proteomic 
characterizations of exosomes from patients revealed high abundance of pro-
inflammatory molecules including leukotriene (LT)-forming enzymes. Large 
portions of the complement system were elevated, and we flagged vitamin D-
binding protein as a possible biomarker for sarcoidosis. Functional tests of patient 
exosomes further suggested that they can engage monocytes and favor release of 
pro-inflammatory cytokines. The effects were partly dependent on LTs, and we 
could reduce cytokine production using the commercially available LT receptor 
antagonist Montelukast. Study IV on exosomes in lung cancer is focused on how 
exosomes may contribute to tumor progression via LTs. Exosomes from pleural 
effusions of patients favored generation of tumorigenic LTD4, as well as tumor cell 
migration, which could be reduced using Montelukast. In summary, this thesis 
highlights the importance of investigating all EV subtypes in both basic and applied 
research. Further, the ability of EVs to contribute to inflammatory processes in the 
lungs underscores the potential of EVs in understanding disease mechanisms and 
finding diagnostic and prognostic disease markers. Finally, all three lung studies II-
IV point to the possibility of interfering with LTs in inflammatory conditions, with 
possible applications also in cancer therapy.  
POPULAR SCIENTIFIC SUMMARY 
Synthetical nanoparticles are developed and used in state-of-the-art applications, 
and offer exciting new technical possibilities. Like many other innovations, nature 
has its own sophisticated equivalence. Every cell type of your body is capable of 
releasing nanoparticles fully loaded with cargo that can be shipped to other cells. 
These biological nanoparticles, or extracellular vesicles (EVs), can be down to 30 
nanometers in diameter. This is extremely small considering that the beard of an 
average man has been anecdotally reported to grow 5-10 nanometers per second! 
Interestingly, these little entities travel around in you, and based on thousands of 
published studies, they seem to contribute to many of your biological functions 
including keeping the immune system in check.  
Research on EVs isolated from blood, urine, or saliva provides clues about how 
diseases affect you via EVs, and explores the potential to diagnose diseases based 
on EVs. Another idea is to use EVs as vaccine or treatment, as they can stimulate 
your own immune system to fight a virus or tumor. 
Exosomes are intensely investigated EVs, and in this thesis we tested also another 
EV type for its ability to stimulate an immune response. We found that both EV types 
could stimulate immune cells in mice, which suggests that treatments based on EVs 
should include both EV types. We also investigated exosomes from patients with the 
lung disease sarcoidosis. These exosomes were enriched in molecules which can 
induce inflammation, and when testing them on blood cells from healthy volunteers, 
they indeed induced inflammatory effects. Lastly, we also tested exosomes from 
lung cancer patients, and found signs that they can help tumor cells to survive and 
possibly also to spread the cancer. Several of these effects depended on molecules 
involved in inflammation. We could reduce several of these inflammatory effects 
using an asthma drug which reduces inflammation, suggesting that this drug may 
protect from cancer progression, and perhaps can be used in inflammatory diseases. 
In summary, we show that several EV types should be tested further for their 
possible use in new treatments, and that they may contribute to inflammations and 
even cancer in the lungs. 
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1 THE IMMUNE SYSTEM 
 
The human immune system has evolved over millions of years to recognize and 
neutralize threats with as little effort and collateral damage as possible. The result is 
a system of enormous complexity. This is a brief overview of the most central 
concepts including lymphocytes and the mononuclear phagocyte system. The 
central aspects of immunity addressed in the studies of this thesis include induction 
of an antigen-specific immune response or inflammation. Immune stimulatory 
mechanisms are therefore mainly described below. 
B CELLS 
B cells comprise follicular B (FOB) cells residing in follicles of peripheral lymphoid 
organs, marginal zone B (MZB) cells of the spleen capturing blood-borne antigens, 
and B1 cells which confer mucosal immunity by monitoring pleural and peritoneal 
cavities. The latter two respond rapidly, and independently of T cells whereas FOB 
cells undergo somatic mutation and affinity maturation in germinal center (GC) 
reactions [1]. B cells are generated in the bone marrow, where their B cell receptor 
(BCR) is assembled from a heavy and a light chain, composed of a unique 
combination of three gene segments (V, D and J). This results in a cell surface-
bound immunoglobulin (Ig) with high specificity for one antigenic epitope. At this 
stage, in the bone marrow, if a BCR recognizes any antigen it is highly likely self-
structures. Any such BCR will therefore be treated as autoreactive, and the B cell will 
undergo receptor editing, basically switching the BCR specificity. Failure to do so will 
induce apoptosis or anergy in the B cell. This central tolerance induction reduces the 
number of mature autoreactive B cells to approximately 10% for adults, still a 
surprisingly high number, which however rarely causes problems as autoreactive B 
cells in the periphery are anergic [2].The BCR can increase its affinity greatly, and be 
produced in great quantities when needed. For this to occur, a GC reaction has to 
take place which is located to peripheral lymphoid organs. B cells are attracted to 
follicles by follicular dendritic cells (FDCs) which release CXCL13 to attract T and B 
cells [3]. The FDCs there display antigen to B cells, which in turn recognize the 
antigen and migrate towards the T cell zone, where antigen-specific T cells meet 
their B cell counterpart. The B cell has now internalized the antigen, processed it and 
here presents it to the CD4+ T follicular helper (TFH) cell, which via its T cell receptor 
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(TCR) recognizes the MHC-antigen complex on the B cell. In return the T cell ligates 
its CD40L to the B cell CD40, which is necessary for the B cell to further differentiate 
either into plasma cells secreting high affinity antibodies, or into memory B cells [4]. 
In parallel with this, some B cells exit the GC early as plasma blasts to generate low 
affinity antibodies. These act as a first line of defense, until the long-lived plasma 
cells are finally produced, releasing high-affinity antibodies. These long-lived PCs 
home to the bone marrow via unknown signaling, and reside there dependent on 
partly unknown mediators which may include IL-6 and TNF [5]. 
Memory B cells are generated via GCs, but can also be formed independently of T 
cell help via mechanisms far less investigated, but generally the T cell-dependent 
(GC-induced) memory B cells generate more robust secondary responses. The 
memory B cells express surface-oriented Ig, and depending on the Ig isotype they 
elicit different secondary responses. IgG+ memory B cells more readily differentiate 
into plasma cells, whereas IgM+ B cells are more prone to re-enter GC reactions. 
They also show great differences in how long they maintain immunological memory, 
i.e. the capacity to induce a robust secondary response [6]. 
T CELLS 
T cells are selected in the thymus for their ability to recognize foreign, but not self, 
peptides presented in self-MHC. T cell progenitors are attracted to the thymus, 
where they stepwise become CD4+CD8+ and are positively selected by cortical 
thymic epithelial cells (cTECs) based on their ability to recognize self-MHC with low 
affinity. Thereafter, the T cells differentiate to single positive cells (CD4+ or CD8+), 
and encounter medullary thymic epithelial cells (mTECs) which display self-antigens, 
and any T cells recognizing self will be deleted in a negative selection process [7]. 
Elegantly, however, a CD4+T cell recognizing self-antigen in the thymus can also 
follow another path and differentiate into a regulatory T cell (Treg) with the capacity 
to modulate tolerance [8]. In pursuit of an antigen, the T cells circulate between the 
blood and lymphoid organs to find an antigen-presenting cell (APC) presenting the 
antigen peptide they recognize. Most commonly, the antigen encounter takes place 
in peripheral lymphoid organs such as a lymph node which represents a crossing 
point for APCs and lymphocytes [9]. 
Necessary for antigen recognition is the T cell receptor (TCR), composed of an 
alpha and a beta chain, which in conjunction with CD3, can engage the MHC-
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peptide complex expressed by an APC. Consequently, the T cell and the APC form 
an immunological synapse, where the TCR-MHC interaction is accompanied by 
association of adhesion molecules including CD54 binding to lymphocyte function-
associated antigen 1 (LFA-1). Further, the T cell is equipped with the immune 
stimulatory receptor CD28, as well as the inhibitory CTLA-4 which both can be 
engaged by the costimulatory CD80/CD86 on the APC. As CD28 interaction with 
CD80/CD86 is a necessity for T cell activation, the competition for CD80/CD86 
provides a tool to steer the T cell response towards immunogenic or tolerogenic 
responses [10]. 
Activated CD8+ T cells differentiate into cytotoxic T lymphocytes (CTL) capable of 
recognizing MHC I with associated peptide, and recognize and kill cells expressing 
foreign peptides derived from pathogens or tumors. CD4+ T cells on the other hand 
rather support other immune cells including CD8+ T cells, B cells, and NK cells to 
tailor the immune response according to the infection or threat. CD4+ T cells can 
differentiate into many subtypes including T helper (Th)1, Th2 and Th17 cells 
depending on the stimulatory environment, including Th-skewing cytokines and 
costimulation [11]. 
Th1 cells are classically described as promoting an immune response to intracellular 
pathogens including viruses, with IFNγ being the hallmark cytokine. Th2 cells on the 
other hand, release IL-4, IL-5 and IL-13, are vital in fighting parasitic infections but 
also play a major role in allergies. Th2 cells are also closely associated with ILC2s, 
which react to epithelial cell-released IL-25 and IL-33 by producing Th2 cytokines 
[12]. 
Th17 cells reside in the intestines during steady state, where the local microbiota 
contributes to Th17 cell development. Here the Th17 cells have an immune 
regulatory role and contribute to maintaining the integrity of the mucosal barrier. 
However, Th17 cells can contribute significantly to inflammatory disorders, a 
pathogenic role which seems to be shaped by environmental factors including 
dietary components and microbiotal imbalance [13]. 
MONONUCLEAR PHAGOCYTES 
Monocytes, DCs and macrophages are closely associated to one another to the 
degree that they are referred to as the mononuclear phagocytes [14]. All three are 
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capable of phagocytosing pathogens, to process them for destruction and antigen 
presentation to other immune cells. Monocytes can differentiate into monocyte-
derived DCs and macrophages, and were previously considered precursors of tissue 
macrophages, whereas more recent appreciations are that tissue macrophages at 
steady state are generally derived from precursor cells seeded in the tissues already 
at embryonic stages [15]. During inflammation, however, there is a substantial 
increase in migration of monocytes into inflamed tissues where they can contribute 
to an expanding pool of macrophages and DCs to participate in resolving the 
inflammation [15]. Monocytes in the blood can be categorized in classical, 
intermediate and non-classical based on their expressions of CD14 and CD16. 
Generally, the classical monocytes (CD14+CD16-) which are the most abundant of 
the three, are considered to have the most potent migratory abilities and respond to 
infection and inflammation by migrating to the affected tissue. The intermediate 
(CD14+CD16+) and the non-classical (CD14-CD16+) are less prone to emigrate from 
circulation, and are dedicated to patrolling the endothelial linings of the blood 
vessels. Of note, the majority of monocyte migration studies are based on mouse 
experiments. There is phenotypic and functional overlap with human monocyte 
counterparts, but there are clearly gaps in the understanding of human monocyte 
behavior in vivo. Monocytes are equipped with chemokine receptors including 
CCR2, upon which they rely for their exit from the bone marrow into systemic 
circulation when stromal cells of the bone marrow releases CCL2. Monocytes 
constitutively migrate to tissues in steady state, but during immunological challenge, 
the trafficking is dramatically increased. Monocytes are attracted to the site of 
inflammation where they undergo substantial transcriptional changes and generate 
pro-inflammatory cytokines such as TNF, and can differentiate to DCs or 
macrophages with inflammatory capacities [16]. Monocytes are also capable of 
presenting antigen, and contribute to mounting adaptive immune responses. When 
activated, they upregulate MHC, costimulatory molecules, and as they are the most 
commonly occurring APC, their contribution to antigen presentation may have been 
underestimated [17]. 
Macrophages are present throughout the body, in most organs and tissues. Their 
phenotype is shaped by the local milieu of cytokines and growth factors. The 
proportions of tissue resident macrophages and monocyte-derived macrophages 
depend on the state of inflammation, and which tissue is affected. Macrophages 
display a vast number of functions. To name a few examples, both in lymph nodes 
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and within the marginal zone (MZ) of the spleen are macrophages which cross-talk 
with B cells to keep them correctly positioned, and display captured antigen to the B 
cells. In the lungs are alveolar macrophages contributing to remove excess amounts 
of surfactant, and in the liver are macrophages (Kupffer cells) which not only monitor 
for pathogens, but also aid in degrading erythrocytes to maintain homeostasis [18]. 
DCs are described as the most professional APCs of the immune system, with high 
expressions of MHC II and costimulatory molecules. To heighten their ability to act 
as immunological sentinels, DCs are also competent cross-presenters, displaying 
external antigenic peptides in MHC I. The ability to present both endogenous and 
exogenous antigens, combined with a high capacity to activate antigen-specific 
lymphocytes is the key to DC supremacy as professional APCs. Categorizing DCs is 
a challenging task. Mouse and human DCs do not fully overlap phenotypically and 
functionally, and in vitro studies of DCs are greatly dependent on the culturing 
conditions including the combination of growth factors present. In a simplified 
manner, however, human DCs can be subdivided into plasmacytoid DCs (pDCs), 
and classical DCs (cDCs). The cDCs can be further divided into cDC1 (CD141+) and 
cDC2 (CD1c+).The pDCs respond vigorously to viral infection, by sensing viral 
components mainly via TLR7 and TLR9, and releasing large amounts of interferons 
as well as cytokines including TNF and IL-6. The cDCs are generally located in 
tissues, and their main roles are to maintain immunological tolerance in steady state, 
and to prime adaptive immune responses against pathogens. CD141+ cDCs are 
mainly described to cross-present antigens to CD8+ T cells, and promote Th1 
responses, whereas CD1c+ cDCs more potently primes CD4+ T cells and are able to 
favor Th1, Th2 or Th17 responses [19]. 
To prevent the risk of DCs priming an immune response to self-antigen, the elegant 
solution is that costimulatory molecule expression on the DCs is required for T cell 
activation. Signals inducing DC-expressed costimulators include TLR ligands, pro-
inflammatory cytokines and the binding of CD40 to CD40 ligand. In absence of such 
signals, costimulatory molecules are not sufficiently expressed to activate the T cells, 
and instead of immunogenic activation the T cells are tolerized. Beyond their ability 
to initiate a specific response, DCs thus play important homeostatic roles in immunity 
[20]. 
DC-based immune therapy of cancer represents a personalized medicine with great 
potential, with the aim of raising an immune response against the tumor. As of 2018, 
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over 200 clinical trials using DC-based vaccines have been conducted, but the 
optimal settings to generate the most efficient vaccines are yet to be established 
[21]. The central concept of DC-vaccines is that antigen-loaded DCs are generated 
and expanded ex vivo, re-infused into the patient where they hopefully encounter T 
and B cells and prime an immune response against the tumor. The phenotype of 
cultured DCs is directly dependent on the culturing conditions and the source of the 
DC precursor cells, whether they are progenitors or monocytes. Further, many 
different antigen loading strategies can be applied, resulting in DCs of greatly varying 
capacity to prime an anti-tumor response in the patients [22, 23]. Melanoma is a 
highly immunogenic cancer type, which is positive when designing DC-based 
vaccines where the aim is to obtain as efficient immune response as possible. 
Several early DC-vaccine studies were aimed at treating melanoma, generally with 
successful inductions of tumor antigen-specific CTLs, but of varying clinical efficacy 
[24-26]. Since then, many cancer types have been included in trials including liver 
and prostate cancer, leukemia and myeloma [21]. DC-based cancer vaccines show 
great promise, but many challenges are yet to be solved, and so far only one 
vaccine has been approved by the US food and drug administration, targeting 
prostate cancer [27]. 
On a final note, innate lymphoid cells (ILCs) are tissue-resident lymphoid-like cells 
derived from lymphoid progenitors, but lacking the highly specific antigen receptors 
of B and T cells. ILCs share T cell properties in terms of transcription factor 
expressions and cytokine production, and are categorized in relationship to their Th 
cell counterparts. ILC1s produce IFNγ, the main Th1 cytokine, whereas ILC2s 
secrete Th2-skewing cytokines including IL-5, IL-9 and IL-13, and ILC3s match the 
Th17 cell cytokine profile including IL-17 and IL-22. Emerging evidence of ILCs in 
immunity suggest they exert a role as sentinels for threats including infection and 
tissue damage, mainly via cytokine receptor expression. Thus, they act as second 
messengers, by responding to a cytokine change induced by other cells, and in turn 
rapidly release their own cytokines. This fine-tuning of immune responses likely 
contributes to steady state homeostasis, but also tumor surveillance and to counter 
infections. ILC dysregulation has been associated with primarily asthma, where ILC2 
activities further amplify an already exaggerated Th2 cytokine response [28, 29]. 
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2 EXTRACELLULAR VESICLES 
 
Extracellular vesicles (EVs) comprise several categories of vesicles released from 
probably all cell types, mediating intercellular communication in steady state and 
disease. Most frequently studied are the exosomes, for which the scientific interest 
has risen to substantial proportions. Other EVs include microvesicles (MVs) and 
apoptotic bodies, which are less investigated. Anecdotally, exosomes are reported in 
nearly 7500 publications, apoptotic bodies and MVs in approximately 3000 
publications each, to be compared e.g. to “innate lymphoid cells” reported in 1600 
publications (PubMed database, August 2018). Apoptotic bodies are generally 
released during apoptosis, and are vehicles for disassembling the dying cell with as 
little immunological effect as possible, and are therefore less suited to function in 
immunogenic settings. There is however a generally increasing understanding that 
the overlap in characteristics and functionality between the EV subtypes is greater 
than previously appreciated, and broad investigations beyond just exosomes are 
warranted. EV nomenclature is still debated, and MVs are sometimes termed 
”microparticles, ”ectosomes” or ”shedding vesicles”. Other EV descriptions are 
based on the cellular origin or function of the EVs e.g. prostasomes released from 
the prostate or tolerosomes which induce immunological tolerance. Attempts have 
been made for a uniform nomenclature, resulting in the agreement to disagree. 
However, the term EVs should refer to all released EVs [30-36], and is used 
throughout this thesis. 
EV BIOGENESIS AND COMPOSITION  
Exosomes are formed when early endosomes mature to late endosomes, and 
undergo an inward budding process which produces intraluminal vesicles (ILV) 
inside the endosomes, which when filled with ILVs are named multivesicular bodies 
(MVB). MVBs have two distinct destinies; fusing with a lysosome to degrade and 
recycle its interior cargo, or fusing with the cell membrane to expel its contents of 
ILVs to the extracellular environment. The fusion with the cell membrane releases 
the ILVs, which are generally 50-100 nm in size, and are thereafter defined as 
exosomes. MVs, on the other hand, are instead formed through pinching of the cell 
membrane, which is an ATP-dependent process involving rearrangements of actin 
cytoskeletal components [37]. MV formation is accompanied by an increase in 
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intracellular Ca2+, resulting in shedding of vesicles being 100-350 nm diameter [32, 
35, 38]. In the original finding of MVs released side-by-side with exosomes, however 
sizes of MV up to 1000nm in diameter [39] were noted.  
Extensive proteomic studies conducted on EVs of various origin has revealed 
thousands of proteins in EVs, which together with the results from some lipidomic 
studies have been added to a common and public database (”Vesiclepedia”) [40]. 
The proteins seemingly most conserved between exosomes of different origins are 
the tetraspanins CD9, CD63 and CD81 [41], as well as components of endosomal 
pathways including ESCRT, TSG101 and Alix [34]. In exosome formation, several 
subtypes of MVBs have been found, and endosomal sorting complexes required for 
transport (ESCRT) believed to be vital for exosome formation can be silenced with 
only partial loss of exosome production [42]. Complete independence of ESCRTs for 
the formation of some exosomes was shown in 2008 when a central concept of 
exosome formation as either ESCRT-dependent or -independent was coined [43]. In 
an attempt to dissect exosome formation mechanisms, Ostrowski et al [44] silenced 
several Rab proteins - members of small GTPases implicated in exosome formation. 
They found that Rab 27a and 27b were vital to exosome biogenesis in their 
experimental settings, but that silencing both proteins was not enough to completely 
abrogate vesicle release. The two Rab proteins were also found to contribute to 
formation of phenotypically different MVBs, suggesting a complex system of vesicle 
biogenesis with redundant and overlapping mechanisms for formation of subtypes of 
EVs. The same research group later blocked the same Rab proteins in tumor cells, 
and this time found that Rab 27a blockade affected tumor growth, presumably via 
decreased exosomal release, whereas 27b blockade had no effect on exosome 
release or tumor growth [45]. Rab 27 silencing also results in release of vesicles with 
reduced CD63, TSG101 and HSP70, whereas CD9 levels remain unchanged [46]. 
These studies point to a complexity of the EV systems, with consequences for the 
research as there are seemingly no EV-exclusive pathways which can be modified 
for investigative purposes. 
As mentioned, it is of increasing interest to distinguish between the EV subtypes to 
evaluate their respective biological activities, but also their potential in applied 
settings. Considering their MVB origin, exosomes should reasonably have 
membrane and cargo composition overlapping with that of late endosomal 
compartments, whereas MVs should carry mainly plasma membrane components.  
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It has however become increasingly clear that the differences between vesicle 
subtypes are more diffuse than previously imagined. The ESCRT components 
involved in exosome formation and some of their interacting molecules e.g. TSG101 
and ALIX are involved also in the release of MV [35], so distinguishing between 
exosomes and MVs based on these markers may not be suitable. Tetraspanins 
have long been considered “exosome markers”, but are also present in cytoplasmic 
membranes, and consequently MV membranes [41]. More recent proteomic 
evaluations of multiple EV subtypes showed that CD9, CD63 and CD81, as well as 
several other markers previously considered exosome-defining were found also in 
EVs corresponding to MVs [47].  
Another possibility would be to segregate EVs based on lipid profiles. Lipid 
compositions of exosomal membranes generally display enrichment of cholesterol, 
phosphatidylserine (PS), and sphingomyelin compared to the cytoplasmic 
membrane [31]. Up to two thirds of small EV components are lipids, based on 
calculations assuming a 5 nm membrane thickness [48]. Despite this, surprisingly 
few broad lipidomic investigations of EVs which could be used to discriminate EV 
subtypes have been conducted. One explanation may be the complexity of lipid 
metabolism, a recent lipidomic analysis of exosomes and MVs detected nearly 2000 
lipid species in the vesicles [49]. Two lipid species enriched in MVs compared to 
exosomes were ceramide and sphingomyelin, but further lipidomic investigations are 
warranted, preferably based on vesicles from several cell types and species. 
Lastly, RNA contents of EVs may also define their subtype and, possibly, 
physiological activity. The finding of functional RNA in EVs [50] spiked interest as it 
opened up a whole new world of intercellular communication in need of investigation. 
There are controversies in EV-RNA research, however. It has been discussed 
whether EV-associated RNA is circulating in quantities high enough to be of 
biological significance. Chevillet et al reported that carefully conducted calculations 
estimate that far less than one miRNA molecule was present per exosome [51]. 
Further, it is unclear whether RNA is tethered to the exosomes or actually inside 
them [52]. This could clearly question whether RNA is indeed packed in EVs or 
merely attached to them during isolation, and if so how this would be of biological 
significance. However, the RNA profiles seem to differ between EV subtypes [53], 
the same for miRNA species [54], and ongoing EV-RNA research is likely to 
contribute to further understanding of EV subtypes within the near future [55]. 
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How specific cargo is incorporated into EVs is not fully understood, but the 
mechanisms involved greatly overlap with those of endosomal recycling and 
intracellular protein sorting. For both exosomes and MVs, cargo is clustered in the 
cytosolic membrane (for MVs) or endosomal membranes (for exosomes) with 
support from tetraspanins. ESCRT components regularly sort proteins tagged by 
ubiquitination into MVBs, for subsequent degradation. As mentioned above, an 
alternative fate of the MVB is to release its contents including ILVs, which then are 
defined as exosomes. By ubiquitinating proteins, they may thus be sorted into MVBs 
of which some will be incorporated in released exosomes [56]. However, 
ubiquitination is not a pre-requisite for sorting into exosomes, as shown by Buschow 
et al who showed that MHC II sorting into exosomes was independent of 
ubiquitination, but depended on CD9 [57]. Further suggestions of tetraspanin-
associated cargo sorting into exosomes include CD81-enriched micro domains 
where proteins are clustered [58], and CD63-mediated sorting into endosomes [59]. 
This tetraspanin-associated cargo loading of exosomes is most strongly associated 
with ESCRT-independent loading [60]. MHC II loading into EVs is expected, as MHC 
II peptide loading occurs in late endosomes [61], coinciding with the site of exosome 
biogenesis. MHC I, on the other hand, is loaded with antigen peptides in the 
endoplasmic reticulum [61] separate from endosomes, so it is interesting that 
exosomes also can express MHC I. ARF6 is a protein involved in intracellular 
trafficking of MHC I and other molecules, and has been shown to regulate 
incorporation of both MHC I and integrins in exosomes [62]. Fully understanding how 
cargo is incorporated into EVs will open for applications aimed at modulating these 
processes. 
CELLULAR UPTAKE OF EVS 
For EVs to convey an intercellular message, the cargo of interest must be 
incorporated and delivered to the right compartment. In vivo, exosomes have been 
found to have short half-life in circulation. The levels of intravenously injected 
exosomes were reduced to half after approximately 2 minutes [63], which has been 
confirmed with exosomes from several different cell sources [64]. This may be 
limiting for certain drug delivery applications where long circulatory half-life often is 
warranted. On the other hand, it may also be an advantage if the EVs are taken up 
by the desired target cell. How to engineer EVs to reach a certain destination is 
complex, but equipping them with surface molecules affecting their uptake is a main 
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approach. To mention some of the molecules on the surface of EVs involved in their 
cell engagement and following uptake, tetraspanins as well as integrins and lectins 
are prime candidates. The optimal set of molecules on EV surfaces for their efficient 
targeting will most likely depend on both which specific exosome population is used, 
as well as properties of the recipient cell type. By blocking molecules on either EVs 
or recipient DCs, Morelli et al [65] elegantly showed that molecules important for 
uptake included phosphatidylserine (PS), tetraspanins CD9 and CD81, CD54, and 
lactadherin on the EVs. On the DC surface, the αv/β3 integrin, and CD54 was most 
important. A similarly conducted experiment later confirmed a role for CD54 also on 
EVs, then binding to LFA-1 on DCs, as well as a role of the lectin DEC-205 on DCs 
for EV uptake [66]. This was supported by the finding that LFA-1 expression on T 
cells was vital for capture of DC-released exosomes [67]. Exosomes from breast 
milk with expressions of mucin-1 (MUC-1) have been shown to partly be dependent 
on the pathogen-recognizing molecule DC-SIGN for their uptake by DCs [68], further 
pointing to surface molecule dependency of EV uptake. B cell-derived exosomes 
were taken up by macrophages of the spleen in a report showing interaction with 
CD169 on the macrophages binding to sialic acids on the exosomes [63]. As 
mentioned above, PS is strongly enriched on exosomes [34], and has for long been 
known as an important component in recognition of apoptotic cells by macrophages 
[69]. Further, EV uptake is reduced if any of the PS-recognizing molecules TIM4 
[70], or Annexin V [67, 71] are blocked, speaking for a role of PS in EV binding to 
target cells. 
After association to the target cells, EVs can be internalized via several possible 
pathways. Substantial evidence point to EV uptake as an active process, including 
dramatically reduced uptake in cold incubations, as well as uptake by fixed cells, and 
by cells with disrupted endocytic pathways [72]. There is evidence of EVs fusing with 
the recipient cell membranes [73, 74], or being phagocytosed [70, 75], the latter 
possibly via PS expression on the EVs [71]. Clathrin-mediated endocytosis (CME) is 
dependent on the binding of ligands to receptors which are anchored by clathrin in 
the recipient cell [76]. This represents the most specific uptake mechanism. CME-
dependent uptake of exosomes have been found [77, 78], which argues for a 
possibility of EVs to engage highly specific targets. Taken together, EVs are able to 
enter cells in many different ways, so therapeutic strategies based on EV uptake, or 
blocking of detrimental EV-communication, must be carefully designed. 
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EVS IN IMMUNITY AND CANCER 
Published findings have shown that EVs are likely released from all cell types and 
transport thousands of proteins, lipids and other molecules. So to define their 
activities is a task as comprehensive as describing what proteins do. However, 
focusing on the role of EVs in the immune system, they have been ascribed both 
stimulatory and inhibitory effects.  
On a brief note, an example of beneficial immune inhibitory EVs is pregnancy-
associated EV release contributing to immune tolerance of fetal tissue. As reviewed 
in [79], placental exosomes seem have immune inhibitory functions and 
downregulate activities of both T cells and NK cells. Interestingly, however, MVs 
from the same source can engage monocytes and B cells to produce a large number 
of pro-inflammatory cytokines including TNF, IFNγ, IL-1β and IL-12 [79].  
Focusing on pathogenic roles of immune inhibitory EVs, however, overwhelming 
evidence show that tumor-derived EVs are important players in cancer. The 
multitude of publications on cancer EVs do not present a uniform picture of their 
phenotype and behavior, but instead point to the complex nature of cancer itself, 
with as many phenotypic variants as can be imagined. Programmed death ligand 1 
(PDL-1) binds PD-1 on immune cells and inhibits their activation. In a study of head 
and neck squamous cell carcinoma (HNSCC), plasma exosomes from 40 patients 
showed a PD-L1 expression correlating strongly to disease activity and the presence 
of lymph node metastasis [80]. Although less clear-cut, glioblastoma EVs have also 
been found to express PD-L1 and prevent T cell activation [81]. Further, tumor EVs 
have been found to induce Treg activity and survival [82], and promote 
immunosuppressive activities of myeloid-derived suppressor cells [83, 84].  
Beyond immune inhibitory effects, tumor EVs have been implicated in metastasis 
mechanisms by promoting cell migration and a tumor-supportive milieu. For 
example, melanoma exosomes can travel to draining lymph nodes to settle there 
and both attract melanoma cells and support the metastatic formation [85]. Further, a 
major finding revealed a role of exosomes in directing metastatic migration, 
preparing a metastatic niche, as well as maintaining a chronic low-level 
inflammation, which is associated with tumor progression [78]. Exosomes from 
tumors metastasizing to the lungs, liver or the brain preferentially engaged cells of 
the destination tissue, and could even alter the metastatic destination of other 
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tumors. The different metastatic destinations were associated with differential 
expressions of integrins on the exosomes [86]. In line with the observed ability of 
exosomes to maintain a low degree of inflammation, Nabet et al found that breast 
cancer cells stimulated fibroblasts to release exosomes carrying RNA species 
recognized as danger-associated molecular patterns (DAMPS) [87]. Other harmful 
cancer EV strategies involve chemo resistance induction and contribution to a 
pathogenic tumor microenvironment (TME). In breast cancer, EVs were shown to 
transport the full mitochondrial genome, and in a tumor model of therapy-resistant 
breast cancer, the delivery of this cargo favored an exit from a dormant state of 
tumor cells [88]. There are plenty of findings supporting the idea that EVs favor 
chemo resistance in tumor cells [89-93]. Further, cancer associated fibroblasts 
(CAF) are stromal cells contributing to tumorigenesis and metastasis by releasing 
cytokines and growth factors, and favoring angiogenesis [94]. Exosomes from 
tumors promote differentiation and tumor-favoring activities of CAF [95, 96], 
supporting the TME. Other EV strategies contributing to a pathological TME induce 
modulating vascularization [97-99], or even to reduce nutrient uptake of non-tumor 
cells [100]. 
EV-BASED IMMUNE THERAPY 
How can we utilize EVs to improve human health? Aside of implementing the 
knowledge gained on basic physiological functions for better understanding of 
human health, the main areas of EV-based medicine are diagnostics and immune 
therapy. To briefly touch upon EV-based diagnostics, the concept is to isolate 
vesicles, preferably from a body fluid accessible with as little invasivity as possible, 
and characterize their cargo, most likely proteins or nucleic acids. RNA transported 
by EVs show different compositional profile compared to healthy subjects in many 
cancer types investigated so far including glioma, breast cancer, colorectal cancer, 
ovarian cancer and melanoma, as reviewed by Jia et al [101]. The first exosome-
based diagnostic tool for cancer has been approved by the US food and drug 
administration (FDA), tested in clinical cohorts of prostate cancer patients and is 
based on a disease-specific pattern of exosomal RNA (www.exosomedx.com). 
Focusing on EV-based therapy, there have been suggestions to interfere with the 
function of harmful EVs in disease, by inhibiting formation, release or uptake of EVs 
[102]. Yet another way could be to reduce the circulatory burden of exosomes, as 
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suggested by Marleau et al, which could be based on techniques already in use to 
reduce viral loads in blood [103]. Interestingly, tetraspanins are involved in all steps 
of cancer metastasis, and tetraspanin-blocking antibodies have shown some 
promise in cancer settings [104]. Antibodies targeting CD9 reduced tumor cell 
proliferation and tumorigenicity in vivo in a colon carcinoma setting [105], and human 
gastric cancer cells implanted in mice showed reduced proliferation and 
angiogenesis [106]. When targeting either CD9 or CD63 with antibodies in a 
metastatic breast cancer model in mice, the metastases to lungs and liver were 
significantly reduced [107]. EVs are strongly enriched in tetraspanins, but whether 
the therapeutic antibodies did target EVs has not been elucidated, and as 
tetraspanins are involved in many cellular processes the risk of off-target effects are 
substantial. Further, as several of the studies mentioned above are based on human 
cancer cells implanted in mice, the therapeutic antibodies used are less likely to 
have side-effects, so in a more realistic setting there is greater risk of unacceptable 
toxicity.  
A more plausible therapeutic implementation of EV knowledge is drug delivery, or 
priming antigen-specific immune responses. It should be mentioned that EVs from 
hematopoietic or mesenchymal stem cells have been proven efficient in inducing 
tissue repair after myocardial infarctions, and tissue damage in kidneys, muscle 
tissue and even pancreatic cells [102]. This thesis is however focused on 
immunogenic EVs for antigen-specific response induction. For cancer vaccination or 
therapy, the most likely approach is using tumor antigen-carrying EVs released from 
APCs [102]. As mentioned above, DCs have been thoroughly tested in nearly 200 
clinical trials with varying success. As tumor cells can induce anergy or apoptosis in 
therapeutic DCs [22, 23], DC-derived EVs represent an attractive alternative 
approach, either alone or in combination with DCs [108]. 
DC-EVs are capable of priming CD8+T cells in vitro and in vivo, and attracted great 
attention when they were found to reduce tumor burden in vivo by inducing an 
antigen-specific T cell-dependent immune response [109]. In dissecting the 
mechanisms behind this, Thery et al found that exosomes activate antigen-specific 
CD4+ T cells in vivo, which was confirmed in vitro but only in the presence of DCs 
[110]. This suggested that EVs need APCs for optimal immunogenicity, but Hwang 
et al showed an ability of EVs to directly prime naive CD8+ T cells in vitro [111]. 
Montecalvo et al found in an engraftment model that donor tissue exosomes did not 
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directly activate T cells but were shuttled via host engraftment-infiltrating DCs to 
splenic DCs, which in turn induced an immune response [112]. Taken together, it is 
highly likely that although EVs may prime T (or B) cells directly, the presence of 
APCs strongly increases the chance of a successful immune response. Further, the 
maturation status of the DCs is of importance for the EV immunogenicity. Exosomes 
from mature DCs are 50-100 times more efficient compared to immature DC-
exosomes in activating naive T cells [113].  Nolte-´t Hoen et al found that DC-
exosomes released during DC-T cell interaction transferred MHC II to the T cells, 
and again that cellular LFA-1 played a central role [67]. Our group demonstrated that 
B cell-derived exosomes from allergy patients presented allergen, induced T cell 
proliferation and favored a Th2-like cytokine release [114]. Further, DC-exosomes 
are far more potent in inducing an antigen-specific immune response if they carry 
both T-, and B cell antigen epitopes, and successful induction of CD8+ T cell 
responses have been found to be dependent on B cells [115, 116].  
In cancer research, phase I clinical trials using patient cell-derived exosomes to 
induce anti-tumor responses have been completed, but with limited clinical 
improvement of patient health status [117, 118]. One possible explanation to the low 
efficacy of the exosomes is that they were derived from immature DCs, but also a 
phase II trial based on mature DC-exosomes showed very modest clinical success 
[119]. The above mentioned B cell dependency could be one reason for this. On the 
positive side, the trials showed little toxicity induced by EVs, which encourages 
continued optimization of EV-based therapy. To just briefly mention other areas of 
EV-based immune therapy, exosomes have been used successfully in vaccine 
models to confer protection against e.g. Mycobacteria [120], avian parasites [121] 
and Leishmanial species [122]. 
TECHNICAL ASPECTS OF EV RESEARCH 
In 1987, Johnstone et al [123] used differential ultracentrifugation (UC) to isolate 
exosomes, and centrifugation is still the most frequently used technique with 
adjusted protocols [124]. Other options of isolation include size exclusion 
chromatography (SEC) and ultrafiltration (UF), all three techniques having 
advantages and limitations [125]. UC is straight-forward and easy to use with all 
sample-contacting equipment easy to sterilize, but initial costs of ultracentrifuges and 
rotors are very high. SEC is most likely to isolate vesicles without disrupting 
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membranes or altering their biological activities [126]. Caveats of the techniques 
include filtration-associated risk of shearing vesicles into smaller fragments and 
clogging filters. UC is also associated with exceptionally high forces leading to 
collapsed and fused vesicles, and SEC requires substantial setup, tuning and 
training, and vesicle isolation is solely based on their size [125]. The choice of 
isolation method will affect downstream analyses of the vesicles, and in ideal several 
methods should be used in parallel, which however often is not feasible.   
Characterization of the vesicles should be conducted using several methods such as 
electron microscopy, ELISA, Western Blot, and conventional flow cytometry in which 
the EVs have to be bound to beads due to their small size [124]. There is increasing 
usage of direct flow cytometry, independent of beads, to analyze EVs. The technique 
is based on tuning the settings of the flow cytometer, and detecting vesicles based 
on fluorescence rather than forward/side scatter properties, however with the 
substantial limitation of a resolution around 100 nm [127]. Transmission electron 
microscopy (TEM) has been frequently used, and is still one of very few imaging 
techniques with resolution high enough to visualize single exosomes. Exosomes are 
commonly noted as having a cup-shaped appearance when imaged by TEM [124], 
and a fully rounded shape when cryo electron microscopy is used [128], a 
consequence of TEM sample preparation where the specimen is dried. 
A method initially developed for industrial nanoparticles, nanoparticle tracking 
analysis (NTA), has been used to measure concentrations and size distributions of 
exosomes. Early versions of the instruments showed large variations in the results 
depending on user and the settings applied [129], with the conclusion that NTA must 
be used with carefully evaluated settings and very well standardized protocols. By 
comparing NTA with other methods for size estimation of EVs, Van der pol et al 
found that ”the minimum detectable vesicle sizes were 70-90 nm for NTA” [130], 
indicating that large portions of all exosomes are outside of the dynamic range of the 
instrument. Further, evaluations of NTA are often conducted using beads, which are 
inherently homogenous in sizes and properties compared to biological vesicles. As 
exosomes span a size range from at least 40-100 nm [34], but up to 30-150 nm [46] 
the smallest and the largest exosomes differ greatly in properties affecting how much 
light they disperse in NTA analysis [130], leading to large potential errors in light 
scattering-based analysis.  
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When studying proteins, inhibiting their release can reveal many clues on their 
functions. As EVs are far more complexly composed entities, no methods are 
available to robustly inhibit their production or release. GW4869 is a compound 
reducing exosome release by inhibiting sphingomyelinases [43], and this has been 
used repeatedly but as it interferes with lipid metabolism it most likely has broad off 
target effects. 
As mentioned above, studies of EV uptake have shown that they are taken up by 
several mechanisms including receptor-mediated endocytosis and membrane fusion 
[72]. However, many of the studies are based on staining EVs with lipophilic dyes 
such as PKH67, R18 or DiL, followed by fluorescence microscopy-based detection 
of EVs, a method with resolution insufficient to detect single EVs [72]. This, taken 
together with the fact that lipophilic dyes themselves may cause aggregation, and 
possibly alter the EV uptake, or leak into the cytoplasmic membranes, speaks for 
that results must be interpreted with caution. However, they may provide important 
clues to EV uptake mechanisms. Touching upon these difficulties in isolation, 
characterization and nomenclature of EVs, attempts have been made to encourage 
broad investigations and very clear descriptions of how experiments were conducted 
in each publication [131].
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3 THE LUNGS 
 
LUNG IMMUNE COMPONENTS 
A consequence of inhaling large volumes of air is exposure of the airways to 
antigens and irritants of the surroundings. Biological and chemical dangers such as 
airborne pathogens, pollen, cigarette smoke, and particulate dust are all constantly 
challenging the airways. The nasal cavity, the pharynx and the lungs are fitted with 
sophisticated defensive systems to counteract infection, and to resolve any insult to 
the barriers shielding us from environmental hazards. Epithelial cells collaborate with 
innate immune cells including granulocytes, DCs, and ILCs, via effector molecules 
including cytokines, chemokines and lipid mediators to confer immunological 
protection in the lungs. 
Epithelial cells compose tight epithelial barriers, the first line of defense against 
aggressors, equipped with cilia and mucus-lined surfaces which capture, immobilize 
and shuttle threats upwards and out of the airways [132]. Beyond a role as physical 
barrier, airway epithelium is actively involved in upholding immunity e.g. by 
monitoring for dangers via pattern recognition receptors (PRRs) including toll-like 
receptors (TLRs) [133] and RIG1 [134]. Upon recognition of pathogens or injury, 
epithelial cells contribute to immune activation in part by producing and secreting 
antimicrobial products including lysozyme, aggressive oxidant species [132], and 
antimicrobial peptides including cathelicidin (LL37) and defensins [132, 135]. 
Epithelial-derived GM-CSF, IL-25 and IL-33 further potently activates DCs, ILCs and 
basophils and inflict airway inflammation [136].  
Mast cells, which can be activated by epithelial signals including IL-33, are 
important players in pulmonary inflammation, capable of releasing potent pro-
inflammatory cytokines, chemokines and pre-formed granules [137]. Mast cells act 
both as sentinels monitoring airways for threat, with a broad repertoire of PRRs, and 
FCε receptors binding IgE antibodies which upon antigen recognition leads to Fc 
receptor crosslinking and consequential release of inflammatory granule contents 
including histamine, TNF and antimicrobial peptides [137]. Mast cells are also an 
important source of eicosanoids including LTs, which can be released already a few 
minutes after activation [137], and mast cell released LTB4 can further enhance the 
inflammation by promoting chemo attraction of mast cell progenitors [138].  
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ILCs (generally described in chapter 1) are lymphoid-like cells lacking antigen 
receptors and instead respond to soluble factors by releasing cytokines modulating 
inflammation [139]. ILC group 2 (ILC2) produce Th2 promoting cytokines including 
IL-4, IL-5 and IL-13 and increased ILC2 activity has been associated to airway 
disorder including asthma [139]. Again speaking for a role of epithelial cells in 
modulating airway inflammation, epithelial cell-derived IL-25 and IL-33 can contribute 
to ILC2 activation, and as IL-33 can activate mast cells it is not surprising that also 
ILC2s appear to co-operate with mast cells. ILC2s and mast cells have been found 
in proximity of one another in the airways [140], and mast cell-released 
prostaglandin D2 (PGD2) potently enhances ILC2 activation mediated by IL-25 and 
IL-33 [140]. So, epithelial cells have the potential to activate both mast cells and 
ILCs, and mast cells add positively to the ILC2 effect via PGD2, which further can 
upregulate the ILC2 receptors for IL-25 and IL-33 [141] leading to a self-amplifying 
spiral of pro-inflammatory events. 
DCs, in conjunction with other innate immune cells of the airways including 
macrophages, and granulocytes, are all components of a robust system to maintain 
immune integrity [142]. Broadly, DCs in the lungs capture and clear pathogens, with 
following tolerogenic or immunogenic response induction [143]. DC populations in 
the lungs are a complicated matter. Based on mainly mouse studies, there are at 
least three defined pulmonary DC subsets, monocyte-derived DC (moDC), 
plasmacytoid DCs (pDCs), and conventional DCs (cDC) which can be divided in 
CD103+ DCs and CD11b+DCs [142]. The two latter DCs are also considered 
migratory, as they are most capable of capturing antigen and transporting it to local 
lymph nodes to prime immune responses. The airways consist of the conducting 
(upper) airways in which relatively few DCs are present, and with low capacity of 
sampling the airway lumen [144], whereas DCs present beneath the epithelial cells 
of the alveoli are richly branching their dendrites into the airway lumen for antigen 
sampling [145].  Infections initiated in the airways stimulate DC activity, influenza e.g. 
triggers antigen-experienced DCs to migrate to draining lymph nodes [146] in a 
CCR7-dependent manner [147] to prime CD8+ T cells to counter the viral infection. 
Also B cells are primed, and antibodies class-switched to IgA are generated to 
reside in the airway mucosa where they can bind and immobilize antigens including 
respiratory viruses, and act together with tissue resident memory T cells which are 
highly abundant in the mucosa and confer protection against pathogens [148]. 
Based on which (migratory) DC subset is performing this activity, effector or memory 
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CD8+T cells are primed [149] to shape the most efficient response to each pathogen 
and circumstance. Connecting back to epithelial cells, the local environment 
including expression of the DC differentiation-inducing FMS-like tyrosine kinase 3 
ligand (FLT3L) affects DC phenotype, and the lungs are supplied with FLT3L likely 
by epithelial cells  [150], pointing to a complex interplay affecting DC phenotype, and 
again involvement of epithelial cells in shaping pulmonary immune components.  
Macrophages are capable of presenting antigen, however alveolar macrophages 
(AMs) are generally inefficient at doing so as they normally have low levels of 
costimulatory molecules [151] and even can inactivate antigen-specific CD4+ T cells 
[152]. AMs develop from embryonically seeded precursors rather than monocytes 
[153], and during steady state they are they are kept in check by epithelial cells via 
both direct contact to inhibitory receptors. Epithelial cell-expressed CD200 binds 
macrophage-expressed CD200R to inhibit pro-inflammatory responses [154]. 
Further, epithelial cells release IL-10 which binds the IL-10R on AMs. Moreover, 
integrins on the epithelial cell surfaces adhere to TGFβ, which in turn binds TGFβ 
receptors on AMs, resulting in an anti-inflammatory state of the AMs, with 
downstream further promotion of FoxP3 expression in T regulatory cells [155]. 
However, during infection or insult, damage to the epithelial cells reduces their IL-10 
production, and disturbs their ability to regulate AMs via TGFβ and CD200 
(mentioned above), resulting in activation of the AMs [156]. The AMs turn into potent 
factories of pro-inflammatory molecules including interferons, IL-12, IL-23 and IL-1β 
which sets off a series of events leading to activation and attraction of lymphoid cells, 
neutrophils and monocytes with a following inflammatory cascade [156].  
Beyond cellular protectors of the airways, eicosanoids are signal mediating lipids 
with substantial impact on pulmonary immunity. Together, the eicosanoids are 
several hundred species with a very large number of biological activities in both 
steady state and disease, most studied are their effects on inflammation [157]. They 
are all derived from arachidonic acid, which can be processed by cyclooxygenases 
(COX enzymes) to form prostanoids including prostaglandins (PGs), by 
lipoxygenases (LOX enzymes) to form LTs, or by cytochrome P450 enzymes 
generating hydroxy-or epoxy-eicosatetranoids [158]. Some of the eicosanoids most 
studied in immunological contexts are prostaglandin E2 (PGE2), a product of the 
COX pathway, and the cysteinyl-LTs (CysLTs) which are products of 5-lipoxygenase 
(5-LO) enzymatic conversion. The enzymes catalyzing each step throughout 
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eicosanoid metabolism are differentially expressed in different cell types, so to most 
efficiently generate eicosanoids e.g. during inflammation, cells harboring different 
intermediates and/or eicosanoid forming enzymes work in concert to complete the 
biogenesis, a behavior termed transcellular eicosanoid biosynthesis [157].  
 
A schematic, simplified, overview of the eicosanoids most relevant to this thesis. Exosomes 
associated to LTA4H and 5-LO are reported in study II, whereas exosomes harboring GGT-
1 are investigated in study IV. 
PGs are often strongly pro-inflammatory, and reducing their biogenesis by inhibiting 
COX enzymes using non-steroidal anti-inflammatory drugs (NSAID) such as aspirin 
is a common strategy to reduce systemic inflammations and fever [157, 158]. 
However, PGs are not inflammatory under all circumstances. PGE2 has four different 
receptors (EP1-EP4), and depending on the expressions of these, PGE2 can even act 
in an anti-inflammatory fashion in the lungs and to dilate bronchi [159]. Notably in a 
cancer setting, PGE2 can even prevent apoptosis in epithelial tumor cells [160]. 
CysLTs, on the other hand, are strongly associated with inflammation. Concerning 
pulmonary disorders they promote bronchoconstriction, as summarized by the LT-
discovering scientist Samuelsson [161], as well as migration of leukocytes including 
neutrophils [162]. In asthma, the levels of CysLTs are highly increased, and amongst 
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detrimental activities in allergies are CysLT-induced increase in vascular 
permeability, attraction and activation of type 2 ILCs as well as elevated airway 
resistance [163]. LTs are targets for therapy in asthma using LT receptor antagonists 
(LTRA) including Montelukast [157, 163].  
SARCOIDOSIS  
Sarcoidosis is an inflammatory disorder of unknown cause. It has the potential to 
affect any organ of the body, and is associated with granuloma formation which can 
lead to irreversible damage. Although it has been studied since it was first described 
in 1869, it is not known what causes sarcoidosis or why some patients are affected 
by an acute form of disease (with better prognosis), whereas other have a slow 
onset disease progression associated with chronicity. Factors complicating research 
on sarcoidosis include a wide heterogeneity of patients and cohorts, complex 
diagnostic procedures and pathological traits overlapping with other diseases. There 
is a great need to understand the disease better, to facilitate diagnostic and 
prognostic procedures and to find new treatment regimens. 
Sarcoidosis results in anything from asymptomatic disease and complete recovery to 
neurological dysfunction and death [164]. Although any organ can be affected, there 
is a clear predominance for symptoms from the lungs (in more than 90% of cases) 
[165]. This thesis is based on investigations of pulmonary sarcoidosis patients, 
whose symptoms most commonly include shortness of breath (dyspnea) and dry 
cough [166].  Generally, 35-40% of sarcoidosis patients presents with the acute form 
of disease [167], known as Löfgren’s syndrome (LS). This after Sven Löfgren, who 
studied patients with signs of swollen hilar lymph nodes (bilateral hilar 
lymphadenopathy, BHL) and subcutaneous inflammations (erythema nodosum 
(EN)), and eventually associated these events with a sarcoidosis patient phenotype 
[168]. The majority of LS patients display with arthritis of the ankle joints, BHL, and 
EN [169], the latter to a larger extent displayed by female patients [170]. LS patients 
generally have a better prognosis, in particular those with the HLA-DRB1*03 
haplotype, which is strongly associated with a complete remission within two years 
[171]. The proportions of patients developing chronic disease also varies with 
studies, but around 25% is commonly reported [172], which is a substantial 
proportion and associates with long-term medication and severe consequences.  
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Epidemiology of sarcoidosis 
Epidemiological numbers vary greatly between studies, and large cohort studies of 
sarcoidosis are few. Sweden is one of the countries with highest sarcoidosis 
prevalence [166], and a large study recently conducted by Arkema et al reported a 
prevalence of 160 per 100´000 inhabitants [173]. This is strikingly higher than in the 
US, where a study on 29´000 US patients found a prevalence of 60 patients per 
100´000 adults [174]. The study further showed that majority of patients were 55 or 
older at time of diagnosis, with a higher prevalence in females and almost threefold 
higher prevalence in African Americans compared to Caucasians [174]. This has 
been supported by other reports, showing up to eightfold higher prevalence in 
African Americans compared to Caucasian Americans [166], and a large cohort 
study reported mortality rates up to twelve times higher for the African Americans 
[175].  
Sarcoidosis diagnostic and therapeutic approaches 
Examination includes lung function test, blood sampling, bronchoscopy with 
bronchoalveolar lavage (BAL), and chest radiography to rule out e.g. tuberculosis 
and define sarcoidosis [176]. The ratio of BAL CD4+ to CD8+ T cells is typically 
elevated (<3.5) in sarcoidosis patients as a result of CD4+ T cell accumulation and 
expansion in BAL. Chest radiography is conducted to certify diagnosis and to stage 
the disease from 0-IV based on degree of pulmonary involvement from none (0) to 
full fibrotic development (IV). Combined with measures to exclude other disease 
such as infections including tuberculosis, and the identification of sarcoid 
granulomas in tissue or lymph node biopsies, a diagnosis is confirmed [176]. 
Searches for biomarkers have so far not resulted in any clinically applied tool. 
Elevated serum levels of angiotensin converting enzyme (ACE), and general 
cytokine profiles associated with inflammation have been observed [176], but not 
proven sufficient to diagnose sarcoidosis. There are reports suggesting possible 
sarcoidosis biomarkers, which include the acute phase protein Serum Amyloid A 
[177], and Chitotriosidase, which is produced by activated macrophages and has 
been associated with sarcoidosis [178, 179].  
Treatment is generally aimed at dampening the symptoms, and initial stage disease 
is usually observed without medical intervention. In later stages, treatments are 
aimed at reducing the risk of fibrotic development, and decreasing inflammation and 
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pain by using corticosteroids, anti-inflammatory agents including NSAID, and 
cytotoxic agents, mainly Methotrexate [166]. In a large US study of more than 9000 
sarcoidosis patients, 23% were pharmacologically treated, the most common 
medication was glucocorticoids with 56% of the patients treated  [174]. 
Corticosteroids are however associated with side effects and toxicity [172], and 
efforts should be made to carefully evaluate its necessity. A recent cohort study 
aimed at reducing corticosteroid usage showed that the antimetabolite drugs 
Methotrexate or Azathioprine could be used to reduce corticosteroid dosage [180]. 
An option for steroid refractory disease is anti-TNF therapy. Infliximab has shown 
improvements in lung function in sarcoidosis patients [181, 182], and Adalimumab 
reduced cough and shortness of breath [183]. As a last resort, the most severely ill 
sarcoidosis patients receive lung transplantation, which however is associated with a 
median survival time of less than six years post transplantation [184]. 
Sarcoidosis genetics 
Familial studies show a higher risk for sarcoidosis in families with at least one patient 
[185, 186]. A recent study of 23´880 sarcoidosis patients in Sweden reported a 3.7-
fold increased risk for sarcoidosis in families with at least one case [187]. A twin 
study showed that for monozygotic siblings to a sarcoidosis patient, the risk of 
disease was increased 80 times [188].  This clearly indicates a genetic component 
contributing to sarcoidosis, one such predisposition seems to include HLA genes. 
HLA-DRB1*03 has long been associated with sarcoidosis [189], in particular with 
acute onset and good prognosis [189], which has been firmly established [171]. Also 
HLA-DQB1*0201 has been associated with a good prognosis [190], although this 
haplotype is closely linked to HLA-DRB1*03. DRB1*04, on the other hand, even 
seems to confer protection against sarcoidosis [189, 191], and HLA-DRB1*01 
protects against sarcoidosis [192], or against chronicity within non-LS patients [167]. 
Further, Berlin et al found that HLA-DRB1*15 was more frequent amongst patients 
with chronic disease [189], and it has been reported that the combined HLA-
DRB1*1501-HLADQB1*0602 predisposes for a worse outcome [193].  
Altogether, there is strong evidence of a genetic predisposition for sarcoidosis based 
on familial studies, as well as beneficial or detrimental associations to HLA 
haplotype. Further, as HLA molecules present antigens to CD4+T cells, it is not 
surprising that particular subsets of CD4+ T cells have been found expanded in 
sarcoidosis.  
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Immunology of sarcoidosis 
A generally accepted hypothesis for how sarcoidosis is induced is that an 
environmental trigger such as a pathogen or a toxic irritant sets off a series of 
immunological events in those who are genetically predisposed, leading to formation 
of granulomas and dissemination of disease [165, 194]. CD4+ T cells are expanded 
in the BAL fluid to the degree that it is included for the diagnostic procedures [195]. 
The CD4/CD8 ratio is however not conclusive evidence of sarcoidosis as the ratio 
can vary greatly [196] and a recent study of sarcoidosis publications conclude that 
the ratio itself should only be used in conjunction with other parameters to diagnose 
sarcoidosis [197]. The role for T cells is however central in sarcoidosis, which is 
typically considered a Th1 skewed disorder [165] with increased expression of 
inflammatory cytokines including IFNγ, IL-1β, IL-6 and TNF [198-200], and generally 
reduced levels of Th2 cytokines [165].  
The central hallmark of sarcoidosis is the granuloma formation, which occurs in 
affected tissues and is the result of a series of immunological events. Granulomas 
consist of a core of epithelioid, and multinucleated giant cells, surrounded by mainly 
CD4+ T cells [201]. TNF is central to granuloma formation [202], and alveolar 
macrophages from sarcoidosis patients release TNF spontaneously [203], and 
vigorously [204] and they are suggested to even be the main source of TNF in 
sarcoidosis patients [205]. Genetic alterations of TNF is associated with increased 
risk of developing sarcoidosis [206], further speaking for a central role of TNF. Other 
key cytokines involved in sarcoidosis include IL-12 and IL-18. The two cytokines in 
combination have synergistic effects leading to favor Th1 skewing by strongly 
increasing production of IFNγ [207, 208], which is central in sarcoid inflammation. 
And, clearly, in sarcoidosis, both IL-12 and IL-18 are elevated in BAL fluid [209, 210], 
and have been proven to favor IFNγ production in the patients [211]. Also the 
epithelial lining fluid of sarcoidosis patients contains elevated IL-18 levels, matching 
an increased expression of the IL-18 receptor on CD4+ T cells in patients, possibly 
amplifying IL-2 generation from these CD4+ T cells [212]. 
What initiates sarcoid inflammation and granuloma formation is not known, and 
putative antigens and triggers have been searched for. Dust exposure and living and 
working near hospital environments have been reported to associate with 
sarcoidosis [198, 213]. Mold, nanoparticles and mycobacteria in working and living 
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environments have also been connected to sarcoidosis, but surprisingly smoking has 
been suggested to correlate with a lower risk of sarcoidosis [214]. It was noted that 
rescue workers of the World Trade Center catastrophe in 2011 presented with higher 
incidence of sarcoidosis-like disease [215]. This has however been questioned, 
referring to insufficient proof of causality [216]. For almost 100 years, mycobacteria 
have been pointed out as a pathogen possibly implicated in sarcoidosis [217]. 
Mycobacterial DNA has been found in 50% of lung samples from sarcoidosis 
patients [217], and the mycobacterial enzyme Mycobacterium tuberculosis catalase-
peroxidase (mKatG) has been found in sarcoidosis patients but not in healthy 
controls [218]. The role of Mycobacteria was further implicated in sarcoidosis by the 
finding of mKatG-reactive T cells in patients [219]. Mycobacterial involvement has 
however not been found in all patient groups and cohorts, and evidence of a 
disease-driving role by mycobacteria is lacking [217]. 
Stronger support of disease-driving antigens have however been found based on 
investigations of T cell receptors. As mentioned above, HLA-DRB1*03 is associated 
with sarcoidosis, although the acute form with good prognosis. When isolating lung 
cells from HLA-DRB1*03-positive sarcoidosis patients and eluting peptides from their 
HLA, Wahlström et al found peptides matching self-antigens including vimentin. 
Further, CD4+ T cells with a specific alpha chain of the TCR have been found 
expanded in patients with HLA-DRB1*03 [220]. Also beta chain variants of the TCR 
has been shown to be expanded in sarcoidosis patients [221], and even a 
combination of alpha and beta chains; Vα 2.3, Vβ 22 [222]. This strongly implies 
reactivity towards a specific antigen or antigens. And, most striking, in a model fitting, 
peptides of the protein vimentin was found to fit perfectly in HLA-DRB1*03 as well as 
matching the Vα 2.3, Vβ 22 TCR [222].  
LUNG CANCER 
Lung cancer is one of the deadliest cancers, and its prevalence is increasing rapidly. 
Beyond the necessity to understand lung cancer mechanism to improve detection 
and treatment regimens from an ethical perspective, there are also enormous 
societal costs associated with lung cancer.  
Epidemiology 
In the US, lung cancer has increased dramatically the past century and cancer-
related death due to lung cancer was before 1940 rare, but has increased by 
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multitudes compared to other cancer forms [223]. Globally, the risk of dying by 
cancer is largest for lung cancer, and lung cancer has been predicted to increase in 
women due to changed smoking habits [224]. The five year survival rate is around 
18% for the US population [225], one reason for very high death rates is the late 
discovery of most cases, at the point where substantial pathological alterations 
throughout the airways are irreversible [225].  
Immunology and pathology  
Lung cancer is divided in subtypes depending on the cellular origin. Non-small cell 
lung cancer (NSCLC) is the most common type, representing around 85% of all 
patients, with the remaining 15% being small cell lung cancer (SCLC) [226]. NSCLC 
is further subdivided in adenocarcinoma, and squamous or large cell cancer, and 
adenocarcinoma is the by far most common diagnose amongst lung cancer patients 
[224, 226]. 
Tumor growth is the result of disturbed cellular homeostasis leading to the classical 
hallmarks of cancer which essentially defines immortal and invasive cells growing 
out of control [227]. The alterations contributing to tumorigenesis are generally 
induced by mutations. For lung cancer it is strongly related with inhaled irritants, 
mainly cigarette smoke, but also exposure to other toxic substances such as 
industrial dust including asbestos fibers, or inhalation of radon gas [228]. For lung 
cancer to metastasize, tumor cells must detach by degrading the surrounding 
extracellular matrix, migrate directly into a neighboring tissue or extravasate into 
blood or lymph circulation, and last settle and form a metastasis [229]. 
Genetical aberrations in lung cancer 
Frequently occurring oncogenic mutations in lung cancer involve proteins with large 
impact on cell growth and differentiation including the epidermal growth factor 
receptor (EGFR), the anaplastic lymphoma kinase (ALK) and KRAS (from Kirsten 
Rat Sarcoma Virus) [226]. The alterations are induced during years of smoking, but 
giving up smoking after many years is no guarantee to safeguard against lung 
cancer. As many smoking-induced alterations represent permanent damage, 
smoking correlates with a lifelong increased risk of lung cancer, and 50% of 
diagnosed cases are ex-smokers [225].   
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Diagnosis and treatment 
The majority of cancer-related deaths are due to metastatic spread, and lung cancer 
is often diagnosed at a point where substantial metastatic spread has already 
occurred [226]. Diagnostic procedures include biopsies of the lungs and affected 
tissues combined with radiology (most frequently computer tomography (CT)) to 
confirm and define the tumor characteristics and stage of disease, which includes 
the degree of spread to lymph nodes [226]. 
Early treatments were entirely based on chemotherapy, with a median survival of 8 
months after diagnosis compared to 4-5 months for untreated lung cancer [230]. 
Improved drug development and usage has increased survival to 12 months [231].  
However, first line of treatment depends on the stage of the disease. Stages I and II 
of (non-small cell) lung cancer are the most uniform stages (later stages are more 
heterogeneous and treatments must be individualized), and are approached with 
surgery to remove tumor mass, whereas stage II to III patients usually undergo 
combined surgery and chemotherapy. Radiotherapy has been reported to actually 
associate with a worse outcome compared to surgery, although comparisons may 
be unfair as there is a bias in which patients are selected for the two treatment 
options. However, more recent  development of radiotherapy, as well as its use as a 
post-operative combination therapy supports its role in at least some patients [232]. 
Immune therapy provides new outsights for treatment, and patients with high 
expressions of the checkpoint blocking (immune inhibitory) PD-L1 are actually 
suggested to receive the PD-1 blocking antibody treatment Pembrolizumab as first 
line of treatment [233]. 
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4 PULMONARY EVS 
 
With their great diversity in phenotype, cargo and mediated effects it is highly likely 
that EVs play roles in intercellular communication also between cells of the airways.  
The airways can be sampled for luminal contents using bronchoalveolar lavage 
(BAL), and the first findings of human airway EVs revealed BAL fluid (BALF) 
exosomes with surface expressions of MHC I and II, costimulatory CD86 and CD54 
[234]. CD54 is a key molecule in immune crosstalk, as it binds LFA-1, which is 
expressed by most leukocytes [235] and mediates adhesion. This cocktail of immune 
stimulatory molecules speaks for that BALF EVs interact with immune cells and 
contribute to disease and/or immune homeostasis. We recently postulated the 
hypothesis that pulmonary EVs even may be a general vehicle initiating or 
aggravating inflammation also in non-pulmonary disorders [236].  
CELLULAR ORIGIN OF LUNG EVS  
An important question in dissecting the roles of EVs in the lungs is what cells they 
originate from. Mapping the EV cell sources is difficult, and further complicating is 
the fact that the condition of the releasing cell affects the EV amounts and 
phenotypes being released. It is thus highly likely that during steady state the 
released EVs differ from those released during inflammation or disease. It is 
tempting to assume that the most numerous cells of the airways are the main source 
of EVs. It is however not necessarily the most common lung EVs that are of greatest 
interest, certainly not so in disease where even a minority of EVs may be 
responsible for pathogenic effects. 
However, considering epithelial cells, they line the entire airways, and it is highly 
likely that epithelial EVs thus are present in the respiratory system. Epithelial cells 
are readily exposed to inhaled antigens and irritants, and it is becoming increasingly 
clear that epithelial cells are important players in pulmonary immunity [237], possibly 
also releasing EVs upon stimuli. Epithelial cells of the bronchi co-express CD63 and 
CD81, which was considered evidence that they are a central source of EVs in the 
lungs [238]. Several findings point to a role of epithelial cell-derived exosomes 
modulating lung immunity by interacting with mononuclear cells. Gazdhar et al 
cultured monocytes in media conditioned by bronchial epithelial cells, which favored 
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expansion of inflammatory monocytes positive for CD141, CD123 and DC-SIGN 
[239]. Further, they found monocytes of the same unique phenotype expanded in 
sarcoidosis patient BAL fluid. Connecting the dots, it is tempting to assume that the 
monocyte-engaging media conditioned by the epithelial cells is indeed enriched in 
EVs. In an attempt to dissect further the role of epithelial exosomes, the exosome 
inhibitor GW4869 [43] (mentioned earlier) was used in an asthma model which 
alleviated symptoms of asthma, presumably by decreasing leukocyte infiltration 
[238], however with the cautionary note that GW4869 most likely has unwanted 
effects beyond reduced exosomal release. In support of a role for epithelial cell-
derived EVs as contributors to inflammation, experiments exposing epithelial cells to 
cigarette smoke extract (CSE) has repeatedly been shown to result in release of pro-
inflammatory EVs. In vitro modeling of chronic obstructive pulmonary disease 
(COPD) showed that epithelial cells released large amounts of exosomes upon 
CSE-stimulation, and that these exosomes contributed to IL-8 production by shuttling 
the protein cysteine-rich angiogenic protein 61 (CCN1), which is associated to 
chronic inflammation in both COPD, RA and cancer [240]. CSE-stimulated bronchial 
epithelial cells release EVs with seemingly pro-fibrotic features including promoting 
differentiation of fibroblasts of the lungs into myofibroblasts [241]. 
The most numerous immune cells in BALF are macrophages. Alveolar 
macrophages (AMs) are central in pulmonary immunity, contributing with 
surveillance and phagocytic capacity. In COPD they are strongly expanded [242], 
and in Sarcoidosis there is a general increase in all leukocytes in the BAL fluid with 
macrophage counts rising several fold [202]. Findings have supported a role for AM-
derived EVs in inflammation in pulmonary compartments, e.g. by reversing IFNγ-
mediated induction of signal transducer and activator of transcription (STAT) [243]. 
They were also found to be taken up by alveolar epithelial cells, speaking for an 
intercellular communication within the lungs mediated by EVs which also could 
transport suppressor of cytokine signaling (SOCS) proteins [243]. Mycobacteria are 
intracellular bacteria infecting alveolar macrophages, which in turn release EVs 
capable of modulating inflammation [244] and even priming CD4+ as well as CD8+ T 
cells [245].   
Although far less frequent than macrophages, granulocytes are present throughout 
the airways, and are a possible source of pulmonary EVs. Eosinophils and 
neutrophils respond to noxious stimuli via pattern recognition receptors, and can 
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release potent pro-inflammatory granules [246, 247]. They both release EVs, 
potentially with cargo modulating inflammation during both steady state and disease. 
Neutrophils are strongly associated with pulmonary disorders including asthma and 
allergy and can release exosomes with antibacterial peptides including 
myeloperoxidase [248]. Interesting from an asthma perspective, where LTs are 
mediating inflammatory effects, neutrophil EVs are capable of transporting 
arachidonic acid, the starting substrate for LT synthesis, to platelets and contribute to 
innate immunity [249]. Again this EV –based crosstalk is more complex than just 
contributing to disease, as it was shown that neutrophilic EVs engaging platelets 
actually reduced the mortality in a model of lung inflammation [249]. For asthma 
patients, cultured eosinophils release more exosomes compared to healthy controls, 
and both healthy and patient eosinophils activated by IFNγ increase EV release 
[250]. The granulocytes perhaps most associated to airway disease are mast cells. 
Mast cells are central in airway immunity, equipped with PRRs and surface-bound 
IgE readily acting upon antigen encounter. They too release EVs, and in an attempt 
to map the proteomes of mast cell EVs, Veerappan et al compared exosomes 
isolated from tracheal aspirations, and from a human mast cell line and found great 
similarities [251] indicating that mast cell EVs indeed are present in human airways. 
Mast cell EVs have further been found to engage both DCs [252], B and T cells 
[253], and endothelial cells [254] to induce maturation, proliferation and activation 
respectively. 
Beyond the innate cells mentioned above, it is possible that also DCs contribute to 
the pool of airway EVs, although DCs are in clear minority compared to most other 
cells of the airways. Considering that sarcoidosis BALF exosomes are enriched in 
MHC II [255], it is however possible that many of them are APC-derived and that e.g. 
DCs play immune modulatory roles in the lungs via EVs. 
T cells are expanded in sarcoidosis, as discussed above, and may be another 
source of pulmonary EVs. T cells release exosome-sized ILVs with cytolytic granules 
[256, 257], and upon activation they release exosomes with incorporated portions of 
the TCR [258]. T cell exosomes may also act as deadly vehicles, as they can 
incorporate membrane-bound Fas ligand [259, 260] and thereby regulate immunity 
by inducing apoptosis in recipient cells. In an in vivo tumor model, T cell exosomes 
induced elevated expression of a metalloproteinase implicated in tumor migration, 
and favored lung tumor invasivity [261]. Activated T cells seem to release exosomes 
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stimulating bystander T cells [262], including promoting CD8+T cell-release of 
IFNγ and granzyme B [263].  
In conclusion, many cell types present throughout the airways are capable of 
releasing EVs with cargo and functions that may contribute to pathological 
development or aggravation in the respiratory system. 
EVS IN LUNG DISEASE 
The Gabrielsson group showed that exosomes with MHC II and costimulatory 
molecules are present in bronchoalveolar lavage fluid (BALF) [234], which directed 
attention to pulmonary EVs. In asthma patients, BALF exosomes have a 
dysregulated miRNA profile [264], carry LT-forming enzymes, and promote LT 
formation and IL-8 generation in bronchial epithelial cells [265]. Asthma patient 
eosinophils release more exosomes compared to healthy controls [250], and 
Kulshreshtha et al reported that IL-13 stimulated epithelial cells released exosomes 
capable of increasing macrophage proliferation and chemotaxis [238].  
Fibrotic diseases including Idiopathic pulmonary fibrosis (IPF) and sarcoidosis have 
also been associated with potentially pathological EVs. IPF patients have serum 
exosomes enriched for micro RNA (miR)-21-5p, which is mostly of biomarker interest 
[266], but may also reveal clues about the disease. IPF involves imbalance in WNT-
protein signaling, and recently, primary lung fibroblasts from IPF patients were found 
to release EVs enriched in WNT-5A, and contribute to fibroblast proliferation and 
TGFβ formation, suggesting EV contribution to IPF [267]. In pulmonary sarcoidosis, 
exosomes isolated from BALF are elevated in numbers and enriched in MCH class I 
and II compared to healthy controls [255]. Patient exosomes further stimulated 
PBMCs to produce more IL-13 and IFNγ, as well as bronchial epithelial cells to 
release more IL-8 compared to healthy exosome stimulations [255]. However, which 
cells within the PBMC compartment that exosomes engage was not studied, leading 
to the design of study III (below) in this thesis. Also in COPD, implications of EV 
involvement have been found, including transport of CCN1 (as mentioned above) by 
exosomes from cigarette smoke-exposed epithelial cells [240], and a suggested 
COPD fibrosis-promoting feature of exosomes via miR-210 [241].  
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In summary, many interesting findings point to a role of exosomes and other EVs in 
lung diseases, but clinical studies on pulmonary EVs are still very few, and this 




Schematic figure of pulmonary EV cargo and effects. Based on the findings of us and 
others, it is clear that EVs from the lungs, but also other compartments, can incorporate both 
nucleic acids and proteins with a potential to engage the immune system in numerous ways. 
VDBP = Vitamin D Binding Protein (study II). 
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5 METHODS  
 
Most methods used in the projects of this thesis are commonly used immunoassays, 
for detailed description see the materials and methods section of each study. EV 
research does, however, involve techniques less commonly used as well as 
adaptations of methods, which may require explanation. For these, a section follows 
below. 
Overview of methods used 
Method Study 
 
I II III IV 
Lipidomics 
   
x 













x x x 
Ultracentrifugation x x x x 




   
Flow cytometry x x x x 
Animal studies x 






Cell culture x 
 
x x 









EV Flow cytometry 
Flow cytometry is designed to detect cells, which are magnitudes larger than EVs, 
and is therefore not suitable for direct acquisition of single EVs. There are alternative 
approaches to solve this issue, including using modified instruments to enhance 
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resolution and setting primary gates according to fluorescence rather than 
forward/side scatter properties [127]. We and others apply a technique based on 
using beads large enough to be detected in the flow cytometer FSC/SSC panel. The 
beads can be coated with antibodies directed against exosome epitopes of choice, 
most commonly we target CD9, CD63 or MHC II. The antibody-coated beads are 
incubated with the EV samples to capture and bind EVs to the beads. The beads are 
washed and the captured EVs can be stained using a conventional flow cytometric 
protocol. The advantage of this adapted flow cytometry is that it requires relatively 
little material (compared to e.g. western blot analysis). It is also robust in the sense 
that the beads are very easily detected in the flow cytometer, and a fluorescent 
signal is only achieved if both a capturing and a detection antibody have bound their 
targets, which reduces false positive signals. The main disadvantage of the method 
is that only a subgroup of EVs are captured, and the choice of capturing antibody will 
strongly affect the results.  
Nanoparticle Tracking Analysis (NTA) 
This technique is based on a converted microscope combined with a laser and a 
high resolution camera. The laser is passed through the sample in a chamber, and 
live video sequences are recorded and analyzed using a designated software. The 
software detects the refracted laser light of each particle in the sample, and tracks its 
movements. All nano-sized entities are constantly vibrating (Brownian motions), and 
these vibrations are proportional to particle size. The NTA software can therefore 
calculate the particle size distribution of the sample. The software also reports 
absolute particle concentration, which we however interpret carefully. The instrument 
is calibrated and tested using monodisperse suspensions of synthetical 
nanoparticles. Aquiring polydisperse, biological samples is associated with a far 
greater complexity including a very large difference in capacity to refract light 
(refractive index) between the smallest and the largest particles. The resulting 
absolute concentrations must therefore be very carefully evaluated, and all technical 
parameters must be strictly controlled not to induce any bias. In study I and II, where 
particle concentration analyses were made using NTA, the results are therefore 
always discussed in relation to another sample, for example between patients and 
healthy volunteer exosomes.
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6 RESULTS AND DISCUSSION 
 
The four projects included in this thesis are built on previous findings of the 
Gabrielsson group and others, indicating immunogenic potential of exosomes. 
Previous findings have contributed to improved engineering of exosomes for immune 
therapy, the discovery of exosomes in human BALF, and exosomal capacities to 
transport and generate LTs.  Study I on exosomes and MVs in vivo was designed to 
further broaden investigations on EVs and shift focus from only exosomes to include 
several EV subtypes. Study II and III are continuations of the discovery of BALF 
exosomes. These clinical collaborations focus on sarcoidosis patient exosomes, and 
in study III also MVs, with the aim to contribute to understanding the disease better 
but also to search for possible biomarkers. Study II presents a substantial proteomic 
characterization of the patient exosomes and a highlights a possible biomarker. 
Many of the proteins upregulated in patients were immune modulatory with potential 
effects on monocytes including chemotaxis. Considering that sarcoidosis is an 
inflammatory disorder, project III was designed to functionally evaluate whether the 
patient EVs can engage and stimulate monocytes to modulate cytokine production. 
Project IV aims at shedding light on the role of exosomes in a lung cancer setting, 
with main focus on their LT-associated effects on tumor cell migration and survival. 
  
STUDY I – EXOSOMES AND MICROVESICLES IN VIVO 
Concept and main findings 
An exciting application where EVs may contribute to human health is immune 
therapy. As exosomes can transport antigen and induce antigen-specific immune 
responses in vivo [268], they have the potential to reach clinical use. Exosomes 
have been intensely investigated since the first reports of their immunogenic 
capacity, whereas MVs have attracted far less attention in these settings. Study I 
was designed to address the abilities of also MVs to generate antigen-specific 
immune responses in vivo. Bone marrow-derived DCs (BMDCs) can be pulsed with 
ovalbumin (OVA), which together with MHC and costimulatory molecules is 
incorporated into BMDC exosomes with OVA-specific immunogenic capacity [109, 
116, 269, 270]. In the current study we expanded the setting to also include MVs 
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isolated from the same BMDC cell cultures, to compare exosomes and MVs side-by-
side.  
Characterizations of the two EV types showed great phenotypic overlap. Similar 
surface marker expressions were found for exosomes and MVs including MHC I and 
II, CD54, CD80, CD86, and CD40. The vesicle size distributions were also similar, 
MVs being slightly larger, and approximately equal numbers of exosomes and MVs 
seemed to be released per cell. EM imaging further showed that exosomes and MVs 
resemble each other morphologically. We thus hypothesized that both EV subtypes 
have immune-modulatory capacities. To evaluate this in vivo, both vesicle types 
were injected into C57Bl/6 mice with a boosting dose after seven days and 
immunological analysis conducted 14 days after the initial immunization. Mice 
immunized with exosomes showed significantly increased proportions of OVA 
pentamer+ CD8+ T cells, as well as OVA-specific IgG production, which is supported 
by previous findings [115, 116, 269]. MVs on the other hand showed no induction of 
CD8+T cell responses, and only a slight production of OVA-specific IgG. Further, the 
proportions of GCB cells were elevated by exosomes only, and surprisingly the 
effect was independent of the OVA antigen being present on the vesicles. In 
IFNγ ELISpot assays, splenocytes from the immunized mice were re-stimulated with 
the whole OVA antigen or either of its MHC I or MHC II immune-dominant peptides. 
When re-stimulating with the MHC I peptide, splenocytes from both exosome-treated 
and MV-treated mice displayed a significant, and equally high, IFNγ response. 
Further, we hypothesized that MVs and exosomes combined may have synergistic 
effects, so mice were also immunized with a combination of the two EVs. However, 
this did not show effects stronger than what the exosomes were inducing. To 
investigate how exosomes have this immunogenic advantage over MVs, we 
analyzed the contents of OVA in the vesicles. Substantially higher levels of OVA 
were found on the surface of the exosomes by ELISA. By western blot analysis, 
OVA was found strongly enriched in exosomes, but OVA was barely detectable in in 
the MVs.  
Discussion 
Exosomes have a history, and promising future, of investigations concerning their 
immunogenicity and possible use in therapy. MVs are most frequently bypassed in 
studies. Accumulating evidence is however indicating that MVs may be more similar 
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to exosomes than previously realized, and on a speculative basis possibly even 
more stimulatory given the right conditions. Our findings that MVs and exosomes 
seem to be fairly similar in size contradict previous appreciations of MVs as much 
larger than exosomes [32]. The size of the vesicles may affect how they traffic 
circulatory systems, and where and how they are taken up, so equal sizes speaks 
for similar abilities from this viewpoint. On a technical note, NTA which was used to 
determine the EV sizes is not suitable for greatly polydispersed samples, and if MVs 
have a very large size span, analyses of these would be more error prone. However, 
by EM imaging we also found quite similar sizes, which is further supported by a 
recent publication [271]. There it was reported that the diameters of DC-derived 
exosomes were 150 nm and MVs 168 nm, to be compared to our findings of 153 nm 
and 170 nm respectively. The overlap also in surface marker expressions further 
strengthens an image of exosomes and MVs as rather close siblings. The 
expressions of syntenin and actinin was, however, inversely expressed in the two 
vesicle pellets, indicating that they are indeed different vesicle types [47], and that 
MVs are not just exosome-contaminated pellets. 
Interestingly, exosomes, but not MVs, induced OVA-specific CD8+ T cells as 
detected by pentamer-based staining, whereas both EVs induced splenocytes to 
react similarly to MHC I peptide re-stimulation. As the re-stimulation is conducted for 
22 hours, it is possible that the two EV types induce CD8+ T cell responses with 
different kinetics. It is thus possible that longer time is needed for MVs to induce their 
strongest effect. Further, although less potent than exosomes, the ability of MVs to 
induce an OVA-specific response is interesting when considering that we found very 
little OVA associated to the MVs by ELISA and no OVA at all by western blot. Is then 
less antigen needed when associated to MVs, suggesting a strong immunogenic 
potential?  
Another intriguing question is how OVA can be taken up by MVs. DCs are capable of 
antigen uptake via several pathways including phagocytosis, macropinocytosis and 
receptor-mediated endocytosis [272]. As all three pathways converge into the MVBs 
[272] where exosomes are formed, it is possible that DC exosomes incorporate 
exogenous antigen. Further, beyond cargo derived from endosomes, exosomes can 
also incorporate molecules from the cytosol as a result of recruitment of cytoplasmic 
components to membrane micro-domains [56]. MVs can be packed with cargo from 
the cytosol in the same manner [56], but clearly not from endosomal compartments. 
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One possibility is, that OVA bound to the surface of the DC would be incorporated 
into forming MVs. As mentioned above, DCs have several options for antigen uptake 
and OVA has been shown to be taken up by micropinocytosis, but mainly by 
receptor-mediated endocytosis dependent on the mannose receptor [273, 274]. In 
our system where OVA is added in enormous amounts, it is possible that phagocytic 
mechanisms of the DCs are saturated. On a speculative basis, this could lead to 
OVA being present both in the cytosol (from where it may be incorporated into MVs), 
as well as stuck to the surface of the DCs bound to receptors such as the mannose 
receptor. Budding MVs would thus be able to depart from the cell with OVA attached 
to them. 
On a final note, we found great overlap in phenotype but distinct functional activities 
of exosomes and MVs. Recently, Tkach et al reported that DC-derived MVs and 
exosomes had very similar stimulatory effects on T cells in vitro [271]. As the two 
studies have nearly identical EV isolation protocols, it is highly interesting to relate 
the findings. Tkach et al found that immature DCs released both exosomes and MVs 
favoring release of Th1-skewing cytokines from primary CD4+ T cells, and after 
maturing the DCs with IFNγ, both exosomes and MVs induced CD4+ T cell 
proliferation equally efficient [271]. Although in vitro evaluations cannot always be 
extrapolated to the in vivo situtation, the study supports our findings of an 
immunogenic potential of MVs. 
 
STUDY II – CHARACTERIZATIONS OF SARCOIDOSIS EXOSOMES 
Concept and main findings 
A main focus of this thesis is pulmonary sarcoidosis, and how EVs may play a role in 
the course of disease, or be exploited for biomarker search. In study II we 
investigated exosomes isolated from the BALF of sarcoidosis patients, to 
characterize their proteomic content and thereby draw a road map for further 
investigation and biomarker search. Patient and healthy control BALF exosomes 
were analyzed by proteomic characterizations, flow cytometry, ELISA and Western 
Blot. 
Flow cytometry was initially used to verify that the exosomes in the current study 
overlap characteristically with what has been published previously. We therefore 
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used beads coated with anti-MHC II as capturing antibodies, as previously published 
[255] and found CD9 and CD63 which verified a vesicular character as well as MHC 
II and CD54, supporting an immune-modulatory role of the exosomes.  
Next, the proteomic analysis detected more than 690 proteins in the BALF 
exosomes, which provides an excellent outsight for further investigation of proteins 
implicated in sarcoidosis, and possibly EV-associated mechanisms in lung diseases 
in general. A brief technical note is that the proteomic technique ITRAQ (isobaric tag 
for relative and absolute quantification) is in the current setting conducted in a semi-
quantitative manner, so protein levels are not reported in absolute amounts. To 
relate the expressions in patients and healthy individuals, all results were therefore 
normalized to internal controls, which were composed of a mix of patient and healthy 
exosomes. The expression of each protein can thus be presented as a proportion 
relative to the internal control, and the relative abundance of each protein is 
presented.  
Many proteins upregulated in patient exosomes were associated with inflammation, 
including immunoglobulins, many components of the complement system, and the 
LT-forming enzyme LTA4H. Of the complement components, C3 was elevated two-
fold on sarcoidosis exosomes, and western blotting validated an enrichment on 
patient exosomes. Vitamin D metabolism is frequently disturbed in sarcoidosis 
patients [166], and we found a clear increase in the Vitamin D binding protein 
(VDBP) in patient exosomes. Indeed, others who investigated the full BALF 
proteome of sarcoidosis patients have highlighted Vitamin D metabolism, and 
multiple components of the complement system [275, 276], and even VDPB [276] as 
strongly elevated in sarcoidosis. We validated the VDBP findings by ELISA, and 
found that VDBP was significantly higher on BALF exosomes from sarcoidosis 
patients compared to healthy control exosomes, but also compared to exosomes 
from six patients with inflammatory lung disorders other than sarcoidosis. To further 
evaluate the potential of exosomal VDBP as biomarker, we also tested exosomes 
isolated from patient serum. Again, we found a significant increase in exosomal 
VDBP for patients compared to healthy. Moreover, when also analyzing whole 





EVs are laborious to investigate, and patient material including BALF adds further 
heterogeneity and complexity. Broad characterizations are therefore highly 
warranted. Our findings in study II of nearly 700 proteins in the BALF exosomes is 
promising for future EV experiments in sarcoidosis, possibly also for other pulmonary 
investigations. Although the patient cohort used in the proteomic characterization 
was quite small (n=15 patients + 5 healthy), the list of proteins can be used both to 
study differences between patient/healthy, but also regardless of differences as a list 
of protein candidates for further pursuit of biomarkers. 
Perhaps most striking, virtually all complement components were increased, 
whereas complement regulatory CD55 was decreased. Both alveolar type II 
epithelial cells and bronchial epithelial cells can produce and release complement 
proteins, and increased complement activity has been reported in lung disorders 
including asthma, IPF, and COPD [277]. Further, previous findings of LT-
components in exosomes [265, 278] were again supported in the current study, now 
in sarcoidosis patient BALF with a different pattern in patients compared to controls. 
LTs are fundamentally associated with inflammatory lung disease including asthma 
[279], and our current findings imply a role for exosomal LTs in lung disorders. 
The findings of increased exosomal VDBP according to both proteomics, and in 
validation experiments was interesting. Sarcoidosis patients frequently show 
dysregulated Vitamin D metabolism, possibly as a consequence of cells within the 
granulomas which are hyperactive in metabolizing Vitamin D [280, 281]. Further, 
beyond transporting Vitamin D to tissues, VDBP can activate macrophages [282] 
and in concert with complement components stimulate chemotaxis of monocytes 
[283] and neutrophils [284]. A speculation is that exosomes carrying VDBP, as well 
as other chemotactic proteins, exit pulmonary compartments and reach circulation 
where they engage immune cells to favor migration.  
From a biomarker point-of-view, although there was an overlap in the levels of 
exosomal VDBP between patients and healthy, one has to consider that this was a 
proof-of-principle that disease-associated markers may be enriched on plasma 
exosomes in sarcoidosis (and other pulmonary disorders for that matter). Refined 
and optimized settings could very well produce diagnostic aid based on EVs, 
especially if several molecules are studied in combination. 
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Sarcoidosis can affect multiple organs, and it is not clear if the disease spreads from 
one organ to another or if it simultaneously develops in several organs. Transplanted 
individuals receiving organs from donors with sarcoidosis have been found to 
develop sarcoidosis [285-289], which speaks for an ability to disseminate. EVs are 
capable of passing the blood-brain-barrier as well as other borders of cellular 
integrity. Further, they have inherent abilities to transport antigen and prime antigen-
specific immune responses, but also to shuttle thousands of proteins and to induce 
pro-inflammatory effects in both innate and adaptive immunity. Is it possible that EVs 
could transfer sarcoidosis-inducing effects between organs? Sarcoidosis is an 
inflammatory disorder, and study II, together with previous reports, indicates that 
exosomes can promote an inflammatory milieu, possibly contributing to sarcoid 
progression. 
 
STUDY III – FUNCTIONAL TESTS OF SARCOIDOSIS EVS 
Concept and main findings 
Previous findings indicated that sarcoidosis BALF exosomes have pro-inflammatory 
effects including induction of IFNγ in autologous PBMCs [255]. Study II further 
highlighted the cargo of sarcoidosis exosomes as enriched in pro-inflammatory 
molecules affecting both innate and adaptive immunity [290]. Study III is a 
continuation of this track, with the aim to functionally evaluate exosomal 
inflammatory capacities. Although sarcoidosis is caused by unclear mechanisms, 
inflammation and granuloma formation are central aspects. In inflammation, innate 
immune cells including neutrophils and monocytes are rapidly recruited to the site of 
inflammation and contribute to inflammatory events [16, 291]. Our findings in study II 
included increased exosomal complement components and VDBP, as well as 
proteins with chemotactic properties on T cells and monocytes (in supplementary 
material, [290]). We therefore hypothesized that BALF exosomes contribute to 
sarcoid inflammation, in part by engaging innate immune cells and induce cytokine 
release, which would accelerate inflammatory events. When stimulating allogeneic 
PBMCs for six hours with patient exosomes, and analyzing the cells by intracellular 
flow cytometry we found that IFNγ was not increased in CD4+ or CD8+ T cells or 
natural killer (NK) cells (the latter potently releasing IFNγ during first hours of 
infection [292]). There was a significant increase of IFNγ in monocytes, however of 
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low magnitude and not with dose-dependency. IFNγ release in the cell cultures was 
also evaluated, but no detectable levels were seen after six or 22 hours. However, 
IL-1β+ monocytes were significantly, and strongly, increased in a dose-dependent 
manner by patient exosomes (but not by healthy control exosomes). To include 
several EV subtypes, and to delineate whether the monocyte effect is dependent on 
bystander PBMCs or is a direct effect on the monocytes, we stimulated either whole 
PBMCs or enriched monocytes with exosomes or MVs. Patient exosomes induced 
significant IL-1β induction on monocytes both within the PBMC population and on 
enriched monocytes, which speaks for a direct activation of the monocytes induced 
by the patient exosomes. MVs had trends of similar effects as the exosomes, but not 
of significant difference to PBS stimulations. We further analyzed the release of 
more innate early cytokines in the supernatants and found IL-6, IL-1β and TNF 
induced by patient, but not healthy, exosomes at six hours and for some also after 
22 hours. Further, CCL2 was strongly induced by the exosomes from a number of 
patients. As study II showed an increase in LT-forming enzymes in patient 
exosomes, we added the LT receptor antagonist Montelukast to investigate whether 
any of these effects were LT-dependent. The high levels of CCL2 induced by some 
patients were significantly reduced by Montelukast. Reactive oxygen species (ROS) 
were also induced in both PBMCs and monocytes by patient exosomes compared to 
healthy exosome stimulations, which adds to an image of pro-inflammatory EVs in 
sarcoidosis. 
Discussion 
We could not detect responses supporting an IFNγ-inducing role of sarcoidosis EVs, 
which was seen in a previous study from our group. It is however possible that the 
discrepancies in these findings are due to the different setup of the two studies.  We 
here used an allogeneic system with healthy donor PBMC recipient cells, whereas 
the previous publication was based on autologous patient recipient cells. Exosomes 
can prime lymphocytes directly, but in allogeneic system there is no self MHC 
recognition and therefore no direct priming of T cells can occur. Looking into other 
early innate cytokines, however, the induction of IL-1β both intracellularly in 
monocytes and released by both PBMCs, and monocytes, was clearly promoted by 
patient exosomes. As also IL-6, TNF, and CCL2 were released significantly more by 
cells stimulated with patient exosomes compared to healthy, this suggests a pro-
inflammatory nature of the sarcoidosis exosomes. The induced cytokines are all 
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implicated in sarcoidosis [293], strengthening the image of EVs contributing to 
sarcoid inflammation.  
The finding that also cultures enriched for monocytes could be induced by 
sarcoidosis exosomes to release the cytokines, was highly interesting, and suggests 
that these cells are a major responder cell to exosomes in the lung. Monocytes have 
also been implicated in sarcoidosis, with expanded intermediate monocytes [294, 
295], which is a population capable of producing large amounts of TNF [296]. 
Strikingly, sarcoidosis patients with expanded intermediate monocytes have been 
shown to have the best response to anti-TNF therapy [297]. It is thus possible that 
exosomes contribute to sarcoid inflammation by engaging monocytes to release pro-
inflammatory cytokines. Monocytes express the CysLT1 receptor [298] and respond 
to LT-mediated signaling, one effect being production of CCL2 [299]. The 
Montelukast-induced reduction of the highest CCL2 response by exosomes provides 
outsight for clinical applications.  
 
STUDY IV – LUNG CANCER PLEURAL EFFUSION EXOSOMES 
Main findings 
Here we studied exosomes isolated from pleural effusions of patients with lung 
cancer to investigate their capacities to promote tumor cell survival and migration by 
modulating LT metabolism. LTs are implicated in cancer, and a lower expression of 
CysLT1R is associated with better prognosis in colorectal [300] and breast cancer 
[301]. One of the most tumorigenic LTs is LTD4, which binds CysLTR1 with high 
affinity [302]. We here found that cultured tumor cells from the PEs of lung cancer 
patients released low levels of LTD4. However, exosomes from the same PEs were 
enriched in the enzyme GGT-1, which converts LTC4 to LTD4. We verified a capacity 
of the exosomes to promote this conversion by adding LTC4, and noted a rapid 
conversion to LTD4. Further, the amounts of LTC4 available for conversion to LTD4 in 
situ may therefore directly limit the tumorigenic effects of PE exosomes. We 
therefore investigated cellular sources of LTC4 in the PEs and found that monocytic 
cells had a greatly increased ability to generate LTs. They had an almost 100-fold 
higher capacity than the mixed cancer cell population in the PEs, strongly suggesting 
that monocytic cells are a plentiful source of LTC4 within the TME. 
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Exosomes have been thoroughly proven to support the TME and favor metastastic 
migration, and to even prepare a metastatic niche [86]. Exosomes from seven lung 
cancer patients were therefore further tested for their capacity to promote migration 
of the lung epithelial cancer-cell line A549, as well as of cells isolated from one of the 
patients. The exosomes clearly accelerated wound healing in a migration assay, 
indicating a potential to favor migration and metastasis of tumor cells in lung cancer. 
The tumor cells isolated from the PE were also sensitive to the CysLT receptor 
antagonist Montelukast, and they could partly be rescued by PE exosomes. 
Discussion 
Study IV expands the scope of this thesis to also touch upon cancer-promoting 
features of exosomes. As mentioned, GGT-1 converts LTC4 to LTD4, and LTD4 
levels have been correlated with cancer in the liver [303], as well as the stomach and 
the lungs [304]. Further, GGT-1 has been found in prostate cancer exosomes and 
even been suggested as a biomarker [305]. Our findings of GGT-1 in the PE 
exosomes are thus supported by previous reports, but also strengthens the 
hypothesis that exosomes contribute to tumorigenic LT formation. The PE exosomal 
capacity to actually also generate LTD4 provided proof that the GGT-1 was indeed 
intact and functional. Moreover, as exosomes promoted cancer cell migration which 
was reduced by Montelukast, it is even clearer that the cancer exosomes use LT 
pathways to contribute to pathogenesis. 
Previous findings have reported that Montelukast interferes with survival or 
progression of lung cancer cells [306], and prostate cancer cells [307], and it was 
found to inhibit tumor growth in a mouse model of colon cancer [308]. We here found 
that Montelukast induced apoptosis in patient tumor cells, and perhaps most 
interestingly that the effect was decreased by PE exosomes. Taken together, PE 
exosomes are enriched in GGT-1 which favors generation of tumorigenic LTD4, and 
they favor migration and survival of cancer cells in a LT-dependent manner. 
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7 CONCLUDING REMARKS 
 
EVs have a potential to revolutionize biological research and human medicine. 
Clinical trials based on EVs have already been conducted, and the number of EV 
publications is increasing exponentially. Previously considered randomly released 
waste disposal vehicles, EVs are today evaluated for their characteristics, functions, 
and potential applications in most areas of medical research. This thesis hopefully 
contributes to the field. 
Study I on MVs and exosomes showed only modest efficacies of the MVs, but even 
so, it is of great importance to consider MVs when designing immune therapies, 
searching for biomarkers, or mapping EV functions. It is highly likely that settings 
optimized for generation of efficient exosomes and MVs are not the same. Thus, 
based on study I, re-evaluating all aspects of cell culturing and antigen-loading may 
very well reveal greater potential of the MVs. Should EV subtypes favor different 
immune responses, one could argue that combined EV populations provide broader 
responses. Or could it be that different EV subtypes are suitable depending on the 
character of the tumor or pathogen against which an immune response is warranted, 
which require different immune responses? 
Sarcoidosis is caused by unclear factors, and diagnostic as well as prognostic 
evaluations are difficult and consume time and resources. The proteomic 
characterization of sarcoidosis exosomes in study II with its validations of selected 
findings provided a long list of protein candidates for biomarker hunting, but also for 
providing clues and perhaps drug targets in the mysterious disorder. Study II and III 
can hopefully contribute to increased understanding of sarcoidosis, but also how 
inflammation may be spread both within pulmonary compartments, but also to 
distant sites. Study IV touches upon cancer, and the role of exosomes, and supports 
findings in study II and III on LT association to lung EVs.   
To what degree EVs play a role in sarcoidosis and lung cancer remains to be fully 
elucidated, but we have found clear indications that pulmonary EVs contribute to 
inflammation. Inflammation is central to many pathologies including sarcoidosis, but 
also to cancer, which is strongly associated with a low level of chronic inflammation. 
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EVs are capable of inducing inflammation via many different mechanisms. 
Exosomes [210] but also MVs [211, 212] can transport IL-1β, and have even been 
suggested to be one of the main exocytic transport mechanisms for IL-1β [309]. 
Inflammations in pulmonary compartments often lead to increased permeability of 
endothelial barriers [218]. Further, in multiple sclerosis (MS) there are inflammatory 
EVs in the affected areas [207-209], which plausibly contributes to degraded 
endothelial integrity [209], and increased leakage across the blood brain barrier 
[208]. There is also plenty of evidence showing that EVs can cross healthy blood 
brain barriers [203-206]. In conclusion, it is possible that EVs deliver their cargo and 
induce effects beyond barriers, either by crossing them or by promoting their 
degradation. 
On a final note, it is highly interesting to connect the inflammatory capacities of EVs 
to their cargo of LT components. Exosome-modulated LT pathways may contribute 
to pathology in multiple lung disorders, presumably also to inflammation in other 
contexts. This underlines the clinical potential for LT receptor antagonists, which are 
safe, well-tolerated, and readily available. 
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